🇺🇸 FDA
Patent

US 11352356

Inhibitors of plasma kallikrein and uses thereof

granted A61PA61P29/00A61P9/00

Quick answer

US patent 11352356 (Inhibitors of plasma kallikrein and uses thereof) held by Takeda Pharmaceutical Company Limited expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61P, A61P29/00, A61P9/00